ArticleTherapeutic advances in urology
Diagnostic value of Xpert
Article in Therapeutic advances in urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Xpert bladder cancer detection and monitor in urothelial carcinoma: systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Evaluating diagnostic performance of urinary biomarkers in the surveillance of non-muscle invasive bladder carcinoma: A systematic review.Investigative and clinical urology · 2025Pooled it
- Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.World journal of urology · 2023Pooled it
- Urine cell-free RNA for bladder cancer detection and treatment response prediction.Nature medicine · 2026Article
- Circulating Tumor Function: A Systems Biology Framework for Liquid Biopsy in Genitourinary Cancers.Genes · 2026Review
- Urinary Biomarkers and Their Role in the Management of Urothelial Carcinoma: A Narrative Review.Journal of clinical medicine · 2026Review
- Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples.International journal of molecular sciences · 2023Review
- Article
- The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers-What Should a Urologist Really Know?International journal of environmental research and public health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsXpert
methodsWe conducted a prospective study on 1015 samples of 416 patients (mean age 72.2 ± 10.3 years) under follow-up for NMIBC. Patients underwent voided urinary cytology, the Xpert
resultsWe identified 168 recurrent tumours: 126 (75%) were low-grade (LG) and 42 (25%) high-grade (HG). Overall sensitivity was 17.9% for cytology, 52.4% for Xpert
conclusionOur data confirm a significantly higher sensitivity of Xpert
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.